Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 66
In phase 3a trials semaglutide shows best in-class
potential on HbA1c reduction across treatment cascade
Comparison of HbA1c lowering effect in SUSTAIN 1, 2, 3, 4 and 5 trials
Sema 1 mg Sema 0.5 mg Placebo Sitagliptin 100 mg Exenatide QW
% patients HbA1c ≤7%
Baseline
0.0
SUSTAIN 1
8.1%
SUSTAIN 2
8.1%
SUSTAIN 3
8.4%
SUSTAIN 4
8.2%
Insulin glargine QD
SUSTAIN 5
8.4%
Change in HbA1c (%)
-0.4
-0.8
0.0
-0.5
-1.2
-1.3
-1.5
-1.5
-1.6
-1.6
-1.6
*
*
-0.9
-1.6
-1.2
-0.8
-1.8
-1.4
-0.1
-2.0
72% 74% 25%
78%
69% 36%
67% 40%
73% 58% 38%
79% 61%
11%
*p < 0.001; QD: once daily; QW: once weekly; sema: semaglutide
Source: Novo Nordisk on file (NN9535-3623, NN9535-3624, NN9535-3625, NN9535-3626, NN9535-3627)
changing
diabetes®
×
novo nordiskView entire presentation